Thymosin alpha-1

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Limited human evidence. Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Laboratory and animal work suggests immune-signaling effects. Mechanistic activity does not establish clinical benefit and may vary by disease context.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Research only

  Thymosin alpha-1 is not FDA approved in the United States. In December 2024, the FDA advisory committee voted against adding it to the 503A bulks list after reviewing effectiveness and safety evidence.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• LL-37Both are studied in immune contexts but act through different pathways.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   FDA Pharmacy Compounding Advisory Committee minutes: thymosin alpha-1

   U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting minutes, December 4, 2024; thymosin alpha-1 review.

   U.S. Food and Drug Administration · Published Dec 4, 2024 · Accessed Jul 22, 2026 · Regulatory source

   Open source